Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.
Status:
Completed
Trial end date:
2013-07-25
Target enrollment:
Participant gender:
Summary
This study is to assess the pharmacokinetics (PK), safety and tolerability of UMEC (62.5µg
and 125µg) and VI (25µg) as monotherapies and combinations in healthy Chinese subjects.